Another study demonstrated that liraglutide, a glucagon-like peptide 1 (GLP-1) agonist for DM patients, may lessen obesity-related fatty liver disease through regulating the sestrin2-mediated Nrf2/HO-1 pathway [129]. Here, GCG is linked to Obesity.